Allergy, Asthma, and Atopic Eczema in Finland

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages Any age
• All sexes
• No healthy volunteers
• Child, Adult, Older adult

Study population: https://www.finnatopy.fi/methods

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden

Conditions

Asthma, Asthma in Children, Allergy, Rhinitis, Allergic, Atopic Dermatitis, Allergen Immunotherapy

Being tested

No intervention, No Intervention: Observational Cohort

Medical subject headings

Asthma, Hypersensitivity, Rhinitis, Allergic, Dermatitis, Atopic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• No interventionOther

  No intervention

• No Intervention: Observational CohortOther

  No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Epidemiology of atopic diseases and allergic sensitization profiles in Finland

   Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis

   Measured: 7 years

2. Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland

   Morbidity, sick leaves, medication use, costs and expences

   Measured: 7 years

3. Evaluate and improve the current use of diagnostic tests for atopic diseases

   Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.

   Measured: 7 years

4. Use and effectiveness of allergen immunotherapy in real world setting

   Real world evidence data using specific cohorts

   Measured: 7 years

5. Direct and indirect costs related to atopic diseases and comorbidities

   All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.

   Measured: 7 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted26 Mar 2024
2. Study start1 Dec 2026 (estimated)
3. Primary completionDec 2032 (estimated)
4. Study completionDec 2034 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for AsthmaStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.